HealthQuill diabetes
obesity
Health

Lilly’s trial results for treating obesity and pre-diabetes are promising

HQ Team November 15, 2024: Eli Lilly’s Phase III trial has yielded positive results from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for.

Read More
The global diabetic population has risen fourfold to 828 million during the last three decades, with more than a quarter living in India, according to an analysis published in The Lancet.
Drugs Health Pharma

Global diabetic population rose fourfold to 828 million in 2022

The global diabetic population has risen fourfold to 828 million during the last three decades, with more than a quarter living in India,.

Read More
Researchers have found genomic variants in one-third of people from the West African countries of Ghana and Nigeria that significantly increase the risk of developing kidney diseases.
Drugs Health Medical

One-third of West Africans have gene variants causing kidney disease

Researchers have found genomic variants in one-third of people from the West African countries of Ghana and Nigeria that significantly increase the risk.

Read More
The US Food and Drug Administration has greenlighted Pfizer Inc.’s respiratory syncytial virus vaccine (RSV) Abrysvo for treating lower respiratory tract disease in people 18-59 years.
Drugs Health Pharma

US drug regulator FDA approves expanded use of Pfizer’s RSV vaccine

The US Food and Drug Administration has greenlighted Pfizer Inc.’s respiratory syncytial virus vaccine (RSV) Abrysvo for treating lower respiratory tract disease in.

Read More
Novo Nordisk will invest 864 million reais ($158 million) to revamp its Brazil unit, which accounts for 25% of the drugmaker’s insulin shipments globally.
Climate Drugs Pharma

Denmark’s Novo Nordisk to invest $158 million in Brazil insulin facility

Novo Nordisk will invest 864 million reais ($158 million) to revamp its Brazil unit, which accounts for 25% of the drugmaker’s insulin shipments.

Read More
Eli Lilly and Company will invest one billion dollars to expand its facility in Ireland to increase its production of drugs to treat Alzheimer’s disease, diabetes and obesity, according to a company statement.
Drugs Health Pharma

Eli Lilly to invest $1b in Irish facility to make Alzheimer’s, obesity drugs

Eli Lilly and Company will invest one billion dollars to expand its facility in Ireland to increase its production of drugs to treat.

Read More
Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to 49 nations in Africa.
Drugs Health Pharma

Eli Lilly to license rheumatoid drug-making technology to Egypt’s EVA

Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to.

Read More
A new cardiovascular disease risk calculator may render 16 million US citizens ineligible for preventive therapy if the current guidelines for cholesterol and high blood pressure treatment remain the same, according to a Harvard Medical School study.
Drugs Health Pharma

New cardiovascular risk calculator may impose a burden on 16 million US citizens

HQ Team August 6, 2024: A new cardiovascular disease risk calculator may render 16 million US citizens ineligible for preventive therapy if the.

Read More
Researchers have added two additional risk factors — untreated vision loss and high LDL cholesterol — to 12 other steps to identify dementia, projected to affect 153 million people by 2050.
Drugs Health Pharma

Untreated vision loss, high LDL cholesterol risk factors for dementia

Researchers have added two additional risk factors — untreated vision loss and high LDL cholesterol — to 12 other steps to identify dementia,.

Read More
French drugmaker Sanofi SA will build a 1.3 billion euro ($1.4 billion) insulin manufacturing facility in Germany’s Frankfurt to secure the long-term supply of the medicine.
Drugs Health Pharma

Sanofi to invest $1.4 billion to build new insulin plant in Frankfurt

French drugmaker Sanofi SA will build a 1.3 billion euro ($1.4 billion) insulin manufacturing facility in Germany’s Frankfurt to secure the long-term supply.

Read More